MIT’s work with Idaho National Laboratory advances America’s nuclear industry
The collaboration has led to new fuels and a variety of other projects to enable clean, safe nuclear energy.
The collaboration has led to new fuels and a variety of other projects to enable clean, safe nuclear energy.
Undergraduate engineering, computer science, and business programs are all No. 1.
With SCIGEN, researchers can steer AI models to create materials with exotic properties for applications like quantum computing.
At the inaugural MIT Generative AI Impact Consortium Symposium, researchers and business leaders discussed potential advancements centered on this powerful technology.
The method enhances 3D bioprinting capabilities, accelerating process optimization for real-world applications in tissue engineering.
MIT researchers have dramatically lowered the error rate of prime editing, a technique that holds potential for treating many genetic disorders.
As the Norman C. Rasmussen Adjunct Professor, George Tynan is looking forward to addressing the big physics and engineering challenges of fusion plasmas.
New findings could provide a way to monitor batteries for sounds that could guide manufacturing, indicate remaining usable life, or flag potential safety issues.
The stand-alone PhD program is building connections and preparing students to make a difference.
MIT-IBM Watson AI Lab researchers have developed a universal guide for estimating how large language models will perform based on smaller models in the same family.
Founder Gregory B. Olson reflects on past and continuing high-impact work as the group turns 40.
MIT CSAIL researchers developed a tool that can model the shape and movements of fetuses in 3D, potentially assisting doctors in finding abnormalities and making diagnoses.
Cache DNA has developed technologies that can preserve biomolecules at room temperature to make storing and transporting samples less expensive and more reliable.
Advance from SMART will help to better identify disease markers and develop targeted therapies and personalized treatment for diseases such as cancer and antibiotic-resistant infection.
A system conceived in Professor Michael Cima’s lab was approved by the Food and Drug Administration after positive results in patients.